Share Name Share Symbol Market Type Share ISIN Share Description
Reckitt Benckiser LSE:RB. London Ordinary Share GB00B24CGK77 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6,393.00p 6,399.00p 6,400.00p - - - 0 06:33:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Household Goods & Home Construction 9,891.0 2,394.0 260.2 24.6 44,945.48

Reckitt Benckiser Share Discussion Threads

Showing 1126 to 1149 of 1150 messages
Chat Pages: 46  45  44  43  42  41  40  39  38  37  36  35  Older
DateSubjectAuthorDiscuss
10/10/2017
08:57
Berenberg says Reckitt Benckiser will bounce back Recovery frustrations have led to a fall in Reckitt Benckiser (RB) shares but Berenberg said the headwinds can be worked through and growth can accelerate at the consumer goods group again. Analyst Rosie Edwards reiterated her ‘buy’ recommendation and target price of £85.00 on the shares, which are down 10% over the last 12 months, taking the price-earnings ratio to what she said was a ‘trough level’. The shares were up 1.6% yesterday at £69.43. ‘Reckitt Benckiser’s recent share price performance is reflective of growing frustration among investors about the company’s top-line recovery, something to which we can relate, having expected to see an improvement in the third quarter of 2017, which will not materialise,’ she said. Edwards said there was ‘little substance’ in conspiracy theories surrounding changes to the executive board and that the company’s ‘competitive advantage in innovation and health still exists, although suffering some knocks in 2016’. ‘Once the headwinds have worked through the system, we expect an acceleration in top-line growth, back to 4% by 2018,’ she said. HTTP://citywire.co.uk/money/the-expert-view-lancashire-reckitt-benckiser-and-wh-smith/a1056936?re=49777&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&utm_campaign=BulkEmail_Money_Daily#i=3
philanderer
09/10/2017
16:26
Berenberg reiterating 'buy' today.
philanderer
06/10/2017
17:58
Crikey, a whole month trapped in a 150p range. Comatose.
johnsonneil1
25/7/2017
08:28
... or not so nicely, depending on one's point of view. Lol
sogoesit
24/7/2017
16:03
Ridiculous rating due to search for sustainable quality. Will it survive a market shakeout because there's a long way to derate.
yf23_1
19/7/2017
10:53
Execution of strategy moving along nicely...
sogoesit
01/6/2017
12:35
WoW, 80 squid... folks like the new deal apparently. I think I will stick my 95p back in here. Edit 06/07: my 95p back to work at 7545p pull-back on weakness (temporary(?) fall in revenue).
sogoesit
25/5/2017
17:03
I think that we must be at an all-time high for RB.
deanforester
12/4/2017
09:54
A bit of a pop, heading for new highs. Apparently some folks like the new deals. 95p ex-dividend tomorrow 13/04.
sogoesit
19/2/2017
19:27
Good. A business (kraft) which can only grow by buying and cost stripping (UK jobs then). No thanks.
bonio10000
19/2/2017
18:06
That's it; over before it began. Kraft Offer withdrawn (Bloomberg).
sogoesit
17/2/2017
14:18
Has the Kraft bid for Unilever put Reckitts in play?
slogsweep
17/2/2017
13:59
Oops; a bid just came in for Unilever from Kraft!! Good for our share price too. Edit: rejected as too low at 18% premium to recent ULVR share price
sogoesit
12/2/2017
17:55
There seem to be a few pundits around that don't like this deal for one reason or another. And, in general, over the years a lot of pundits have preferred Unilever over Reckitt for the reason that it is more "diversified" having food as a major part of its brand holdings. I wonder if these are the same pundits or not? Reckitt has outperformed ULVR over the long term (5+ years) excluding dividends. I only hold one, Reckitt, as they are highly correlated otherwise than in Reckitt's long term performance.
sogoesit
12/2/2017
10:27
The Sunday Times: Reckitt Benckiser is facing a shareholder uprising over accusations that its $16.6 billion (£13.3 billion) deal to buy a US rival will guarantee its boss enormous future bonuses. HTTP://citywire.co.uk/money/sunday-papers-investors-draw-up-sin-bin-solution-to-executive-pay/a991094
philanderer
10/2/2017
14:09
10th feb Whitman Howard buy tp 9000p 10th feb Liberum buy tp 7650p reiterations
philanderer
10/2/2017
11:34
Nothing wrong with those results.
deanforester
06/2/2017
13:59
Reckitt Benckiser chief Rakesh Kapoor in line for £15m windfall from Mead Johnson deal HTTP://www.standard.co.uk/business/reckitt-benckiser-chief-rakesh-kapoor-in-line-for-15m-windfall-from-mead-johnson-deal-a3459261.html
philanderer
03/2/2017
18:11
Looks like the Mead Johnson news helped a little. Pity that the early rise wasn't carried through.
deanforester
02/2/2017
09:54
Maybe a bit of diversification is healthy if consumer healthcare opportunities are limited and/or too expensive. I was hoping Pfizer's consumer healthcare might come under its wing but that looks like it isn't going to happen now.
minerve
02/2/2017
08:18
Interesting move into baby foods... one of the original "Johnson & Johnson" businesses from what I read. Looks good for the share price in any case and no equity raising.
sogoesit
16/1/2017
18:34
16th jan Jefferies buy tp 7750p
philanderer
04/5/2016
11:36
Very concerned over the situation in South Korea, following on from the Australian fines, I think the BOD need to report more thoroughly on the far eastern operations.
footrot355
21/2/2016
20:29
Great results for 2015 & no reason why it cannot outperform UK100 in 2016: ommenting on these results, Rakesh Kapoor, Chief Executive Officer, said: "RB delivered excellent growth and margin expansion in 2015 as a result of our continued focus on our Health, Hygiene and Home Powerbrand portfolio and supported by our culture of innovation and agility. Despite a year of mixed market conditions, we achieved broad-based growth (+6% LFL), across both developed and developing markets. This was led by an exceptional performance in Consumer Health, due to both a strong flu season at the beginning of the year and outstanding performances from our innovations on brands such as Scholl, Durex, Nurofen and Strepsils. Our virtuous earnings model continued to deliver in 2015 and resulted in significant value creation for shareholders. Strong gross margin expansion, combined with accelerated indirect cost savings from our Supercharge programme, created room in our P&L to both increase our brand equity investment (BEI) and to deliver exceptional operating margin expansion. We continue to expect Supercharge to lead to GBP150m in cost savings over three years, but have achieved a significant portion of those savings within the first year. In 2016, we expect that the macro environment will be tough, but remain confident that our strategic choices across Powerbrands and Powermarkets will enable RB to deliver another year of growth and margin expansion. We are targeting LFL net revenue growth of +4-5%(1) . For operating margin(2) , we reiterate our medium term target of moderate margin expansion. We expect this to be supplemented in 2016 by part of the remaining Project Supercharge efficiencies."
jdb2005
Chat Pages: 46  45  44  43  42  41  40  39  38  37  36  35  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171120 07:48:46